85. 特発性間質性肺炎 Disease details / Clinical trials / Drug dev / DR info

(18)F-FDG   
   Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
      2010   -   EUCTR2010-020223-44-AT   Austria;
00258901   
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
00322900   
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
18F-FDG   
   Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui
      2007   -   JPRN-UMIN000010498   Japan;
3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt   
   Vicore Pharma AB
      2020   Phase 2   EUCTR2020-000822-24-GB   Ukraine;United Kingdom;
534-1508   
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
68Ga-BMV101   
   Peking Union Medical College Hospital
      2015   Early Phase 1   NCT02485886   China;
ACT-064992   
   ACTELION Pharmaceuticals Ltd.
      2011   -   EUCTR2010-024211-13-SI   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
      2011   -   EUCTR2010-024211-13-SE   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
      2011   -   EUCTR2010-024211-13-ES   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
      2011   -   EUCTR2010-024211-13-DE   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
   Actelion Pharamceuticals Ltd
      2010   -   EUCTR2008-006054-17-IT   France;Germany;Italy;Slovenia;Spain;Sweden;
   Actelion Pharmaceuticals Ltd.
      2009   Phase 2   EUCTR2008-006054-17-ES   France;Germany;Italy;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-006054-17-SI   France;Germany;Italy;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-006054-17-SE   France;Germany;Italy;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-006054-17-FR   France;Germany;Italy;Slovenia;Spain;Sweden;
      -   -   EUCTR2008-006054-17-DE   France;Germany;Italy;Slovenia;Spain;Sweden;
ACT-064992 (macitentan)   
   Actelion
      2009   Phase 2   NCT00903331   Australia;Canada;France;Germany;Israel;Italy;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
AP01   
   Avalyn Pharma, Inc.
      2021   Phase 2   EUCTR2020-005103-39-PL   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
      2021   Phase 2   EUCTR2020-005103-39-CZ   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
ART-123   
   ASAHI KASEI PHARMA CORPORATION
      2016   Phase 3   JPRN-JapicCTI-163326   -
   Asahi Kasei Pharma Corporation
      2016   Phase 3   NCT02739165   Japan;
AT 10   
   Makino Ryoko
      2021   Phase 3   JPRN-jRCT2051210129   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
AZAPRED   
   Thorax National Institute
      2005   -   NCT00518310   Chile;
AZD5055   
   AstraZeneca
      2021   Phase 1   NCT05134727   United States;
Acetylcysteine   
   Saitama Red Cross Hospital
      2013   -   JPRN-UMIN000016706   Japan;
   Shanghai Pulmonary Hospital, Tongji University School of Medicine
      2020   -   ChiCTR2000031386   China;
Aerosol interferon-gamma   
   NYU Langone Health
      2007   Phase 1   NCT00563212   United States;
Air   
   Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
      2009   -   JPRN-UMIN000016045   Japan;
   Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
      2015   -   JPRN-UMIN000015508   Japan;
Alemtuzumab   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
AlloRx   
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05016817   Antigua and Barbuda;
Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)   
   Joshua M Hare
      2013   Phase 1   NCT02013700   United States;
Ambrisentan   
   Gilead Sciences
      2009   Phase 3   NCT00879229   Australia;Austria;Belgium;Canada;Germany;Ireland;Israel;Italy;United Kingdom;United States;
      2008   Phase 3   NCT00768300   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;France;Germany;Ireland;Israel;Italy;Mexico;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States;
   Gilead Sciences Incorporated
      2010   -   EUCTR2008-004405-34-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-004405-34-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      -   -   EUCTR2008-004405-34-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Gilead Sciences, Inc
      2009   -   EUCTR2009-011169-98-GB   Austria;Czech Republic;Germany;Italy;United Kingdom;
      2009   -   EUCTR2009-011169-98-DE   Austria;Czech Republic;Germany;Italy;United Kingdom;
      2009   -   EUCTR2009-011169-98-AT   Austria;Czech Republic;Germany;Italy;United Kingdom;
   Gilead Sciences, Inc.
      2011   -   EUCTR2009-011169-98-CZ   Austria;Czech Republic;Germany;Italy;United Kingdom;
Antimicrobial therapy: Co-trimoxazole or Doxycycline   
   Weill Medical College of Cornell University
      2017   Phase 3   NCT02759120   United States;
Atezolizumab   
   KATO Terufumi
      2019   Phase 2   JPRN-jRCTs031190084   Japan;
Auto-titrating oxygen system   
   Imperial College London
      2014   -   NCT02248064   United Kingdom;
Autoantibody Reductive Therapy   
   University of Alabama at Birmingham
      2018   Phase 2   NCT03286556   United States;
Autologous Adipose Derived MSCs (ADMSCs)   
   Kasiak Research Pvt. Ltd.
      2014   Phase 1/Phase 2   NCT02135380   India;
Autologous Stromal Vascular Fraction (SVF)   
   Kasiak Research Pvt. Ltd.
      2014   Phase 1/Phase 2   NCT02135380   India;
Autologous mesenchymal stem cells derived from bone marrow   
   Clinica Universidad de Navarra, Universidad de Navarra
      2013   Phase 1   NCT01919827   Spain;
Aviptadil, 66 microgram/mL   
   Mondobiotech Laboratories Anstalt
      2006   -   EUCTR2006-002174-22-DE   Germany;
Azathioprine   
   InterMune
      2002   Phase 3   NCT00052039   Italy;
Azathioprine/prednisone   
   University of Michigan
      2001   Phase 2   NCT00262405   United States;
Azithromycin   
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
   University Hospital Inselspital, Berne
      2014   -   NCT02173145   Switzerland;
BBT-877, Multiple doses   
   Bridge Biotherapeutics, Inc.
      2019   Phase 1   NCT03830125   United States;
BBT-877, Single dose   
   Bridge Biotherapeutics, Inc.
      2019   Phase 1   NCT03830125   United States;
BG00011   
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2017-003158-18-IT   Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Biogen
      2018   Phase 2   NCT03573505   Argentina;Australia;Belgium;Chile;Czechia;Denmark;France;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2012   Phase 2   NCT01371305   United States;
   Biogen Idec Research Limited
      2019   Phase 2   EUCTR2017-003158-18-PL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003158-18-DE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-NL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-GR   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-GB   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-ES   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-DK   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-CZ   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-BE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
BI 1015550   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2019-004167-45-IT   Australia;Austria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim
      2020   Phase 2   NCT04419506   Argentina;Australia;Austria;Canada;Chile;China;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004167-45-NL   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2018   Phase 1   NCT03422068   Belgium;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   Boehringer Ingelheim B.V.
      2020   Phase 2   EUCTR2019-004167-45-DK   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2020   Phase 2   EUCTR2019-004167-45-FI   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2020   Phase 2   EUCTR2019-004167-45-GB   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2019-004167-45-DE   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2019-004167-45-CZ   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004167-45-SK   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004167-45-PL   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004167-45-HU   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004167-45-AT   Argentina;Australia;Austria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
BIBF 1120   
   BOEHRINGER ING.
      2012   Phase 3   EUCTR2011-002766-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024251-87-IT   Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
      2010   Phase 2   EUCTR2009-013788-21-IT   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim
      2012   Phase 3   NCT01619085   Australia;Belgium;Canada;Chile;China;Czech Republic;Czechia;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002766-21-FI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2011   Phase 3   NCT01335477   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
      2011   Phase 3   NCT01335464   Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
      2011   -   EUCTR2010-024252-29-NL   Finland;Germany;Greece;Netherlands;Portugal;Spain;
      2011   -   EUCTR2010-024252-29-GR   Finland;Germany;Greece;Netherlands;Portugal;Spain;
      2011   -   EUCTR2010-024252-29-FI   Finland;Germany;Greece;Netherlands;Portugal;Spain;
      2010   Phase 2   NCT01170065   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
      2010   Phase 2   NCT01136174   Japan;
      2008   -   EUCTR2006-002875-42-GR   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-002875-42-GB   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-002875-42-IE   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-002875-42-DE   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Hellas
      2012   Phase 3   EUCTR2011-002766-21-GR   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Boehringer Ingelheim Ellas AE
      2010   -   EUCTR2009-013788-21-GR   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim España S.A
      2012   Phase 3   EUCTR2011-002766-21-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Boehringer Ingelheim España S.A.
      2010   -   EUCTR2009-013788-21-ES   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim España, S.A.
      2011   Phase 3   EUCTR2010-024252-29-ES   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
      2007   -   EUCTR2006-002875-42-ES   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim France
      2011   -   EUCTR2010-024252-29-PT   Canada;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United States;
      2010   Phase 2   EUCTR2009-013788-21-FR   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2006-002875-42-PT   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim France SAS
      2007   Phase 2   EUCTR2006-002875-42-FR   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Limited
      2013   Phase 3   EUCTR2011-002766-21-IE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002766-21-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024251-87-GB   Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
      2011   -   EUCTR2010-024251-87-IE   Belgium;Czech Republic;Germany;Ireland;Italy;United Kingdom;
      2010   Phase 2   EUCTR2009-013788-21-GB   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Ltd
      2010   Phase 2   EUCTR2009-013788-21-IE   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Pharma Ges mbH
      2008   -   EUCTR2006-002875-42-BG   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-002875-42-CZ   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2012   Phase 3   EUCTR2011-002766-21-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-024252-29-DE   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
      2011   -   EUCTR2010-024251-87-DE   Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-013788-21-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
   Boehringer Ingelheim RCV Ges mbH & Co KG
      2007   -   EUCTR2006-002875-42-HU   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmBH & Co KG
      2011   -   EUCTR2010-024251-87-CZ   Argentina;Australia;Belgium;Brazil;China;Czech Republic;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-013788-21-HU   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2009-013788-21-BG   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmbH & Co KG
      2012   Phase 3   EUCTR2011-002766-21-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-013788-21-CZ   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom;
   Boehringer Ingelheim bv
      2007   -   EUCTR2006-002875-42-NL   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   SCS Boehringer Ingelheim Comm.V
      2011   Phase 3   EUCTR2010-024251-87-BE   Argentina;Australia;Belgium;Brazil;China;Czech Republic;France;Germany;India;Ireland;Israel;Italy;Japan;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-013788-21-BE   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-002875-42-BE   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   SCS Boehringer Ingelheim Ingelheim Comm.V
      2012   Phase 3   EUCTR2011-002766-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2012   Phase 3   EUCTR2011-002766-21-PT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Unilfarma, Lda.
      2010   Phase 2   EUCTR2009-013788-21-PT   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
BIBF 1120 ES   
   BOEHRINGER ING.
      2007   -   EUCTR2006-002875-42-IT   Belgium;Bulgaria;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
BIBF1120   
   Boehringer Ingelheim España, S.A.
      2011   Phase 3   EUCTR2010-024252-29-ES   Canada;Chile;China;Finland;France;Germany;Greece;India;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United States;
BLD-2660   
   Blade Therapeutics
      2019   Phase 2   NCT04244825   United Kingdom;
   Blade Therapeutics, Inc.
      2020   Phase 2   EUCTR2019-004998-34-GB   United Kingdom;
BMS-986020   
   Bristol-Myers Squibb
      2013   Phase 2   NCT01766817   Australia;Chile;Colombia;Mexico;Peru;United States;
BMS-986278   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2020   Phase 2   EUCTR2019-003992-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb
      2019   Phase 1   NCT03981094   United States;
   Bristol-Myers Squibb International Corporation
      2020   Phase 2   EUCTR2019-003992-21-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003992-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Bardoxolone methyl   
   Reata Pharmaceuticals, Inc.
      2014   Phase 2   NCT02036970   Germany;Spain;United Kingdom;United States;
Beclometasone dipropionate   
   Hull and East Yorkshire Hospitals NHS Trust
      2014   -   EUCTR2013-004404-19-GB   United Kingdom;
Bevacizumab   
   IP lung cancer study group
      2012   -   JPRN-UMIN000018322   Japan;
   Katakami Nobuyuki
      2013   Phase 2   JPRN-jRCTs061180046   Japan;
Blood sample collection   
   Rennes University Hospital
      2014   -   NCT04016168   France;
Bone marrow mesenchymal stem cells   
   Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
      2013   Phase 1/Phase 2   NCT02594839   Russian Federation;
Bosentan   
   Actelion
      2008   Phase 3   NCT00631475   Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Spain;Switzerland;United Kingdom;United States;
      2007   Phase 3   NCT00391443   Australia;Austria;Belgium;Canada;Croatia;Czech Republic;Denmark;Former Serbia and Montenegro;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2003   Phase 2/Phase 3   NCT00071461   Canada;France;Germany;Israel;Italy;Switzerland;United Kingdom;United States;
   Actelion Registration Ltd
      2008   -   EUCTR2007-001741-18-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School
      2011   -   JPRN-UMIN000004749   Japan;
   Rajan Saggar
      2007   Phase 4   NCT00625469   United States;
   Royal Brompton & Harefield NHS Foundation Trust
      2008   Phase 4   NCT00637065   United Kingdom;
Broncho-Vaxom   
   Shanghai Pulmonary Hospital
      2015   -   ChiCTR-OOC-15005840   China;
Bronchoalveolar lavage (BAL fluid)   
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2021   -   NCT05007340   Canada;
C21   
   Vicore Pharma AB
      2020   Phase 2   NCT04533022   India;Russian Federation;Ukraine;United Kingdom;
      2020   Phase 2   EUCTR2020-000822-24-GB   Ukraine;United Kingdom;
      2018   Phase 2   EUCTR2017-004923-63-GB   Bulgaria;Poland;Serbia;United Kingdom;
CBDCA   
   Lung Oncology Group in Kyushu, Japan (LOGIK)
      2007   -   JPRN-UMIN000015929   Japan;
CC-90001   
   Celgene
      2017   Phase 2   NCT03142191   Australia;Brazil;Canada;China;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Celgene Corporation
      2017   Phase 2   EUCTR2016-003473-17-GR   Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003473-17-GB   Australia;Brazil;Canada;Colombia;France;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
CC-930   
   Celgene
      2011   Phase 2   NCT01203943   Canada;United States;
CD3/CD19 negative hematopoietic stem cells   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
CNTO 888   
   Centocor, Inc.
      2008   Phase 2   NCT00786201   Belgium;Canada;Germany;Netherlands;United States;
CNTO888   
   Centocor B.V.
      2009   -   EUCTR2008-001281-86-NL   Belgium;Germany;Netherlands;
   Janssen Biologics B.V.
      2010   -   EUCTR2008-001281-86-DE   Belgium;Germany;Netherlands;
      2009   Phase 2   EUCTR2008-001281-86-BE   Belgium;Germany;Netherlands;
COMPOUND 21   
   Vicore Pharma AB
      2018   Phase 2   EUCTR2017-004923-63-GB   Bulgaria;Poland;Serbia;United Kingdom;
CSL312   
   CSL Behring
      2022   Phase 2   NCT05130970   Canada;United States;
Carboplatin   
   Fujimoto Daichi
      2021   -   JPRN-jRCTs051200109   Japan;
   Hirosaki University Graduate School of Medicine
      2016   -   JPRN-UMIN000021591   Japan;
   IKEDA Satoshi
      2019   Phase 2   JPRN-jRCTs031190119   Japan;
   IP lung cancer study group
      2012   -   JPRN-UMIN000018322   Japan;
      2012   -   JPRN-UMIN000018248   Japan;
   Katakami Nobuyuki
      2013   Phase 2   JPRN-jRCTs061180046   Japan;
      2013   Phase 2   JPRN-jRCTs051180149   Japan;
   Lung Oncology Group in Kyushu, Japan (LOGIK)
      2007   -   JPRN-UMIN000015929   Japan;
   Okamoto Isamu
      2017   Phase 3   JPRN-jRCTs071180049   Japan;
   Research Institute for Diseases of the Chest, Kyushu University
      2017   Phase 3   JPRN-UMIN000026799   Japan;
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)   
   Lung Therapeutics, Inc
      2020   Phase 1   NCT04233814   United Kingdom;
Centricyte 1000   
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States;
Combination Product: EGCG + Nintedanib   
   Hal Chapman
      2022   Phase 1   NCT05195918   United States;
Combination Product: EGCG + Pirfenidone   
   Hal Chapman
      2022   Phase 1   NCT05195918   United States;
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids   
   Michael Donahoe
      2011   Phase 1/Phase 2   NCT01266317   United States;
Corticosteroid (prednisolone)   
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 3   NCT02460588   France;
Cotrimoxazole   
   Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
      2013   Phase 3   NCT01777737   Spain;
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom;
Cravit   
   Respiratory Department, Peking Union Medical College Hospital
      2011   -   ChiCTR-TRC-12002372   China;
Cromolyn Sodium   
   University of California, San Francisco
      2015   Phase 1   NCT01841307   United States;
Cromolyn sodio (cromoglicato disodico, DSCG)   
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Cromolyn sodium [Disodium Cromoglycate]   
   Respivant Sciences GmbH
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Cyclophosphamide   
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 3   NCT02460588   France;
   Peking Union Medical College Hospital
      2019   Phase 4   ChiCTR1900027121   China;
Cyclosphamine   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 3   EUCTR2015-000492-27-FR   France;
DEX284   
   Galecto Biotech AB
      2020   Phase 2   EUCTR2018-002664-73-IE   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-PL   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-IT   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-GB   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-FR   Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-ES   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
DWN12088   
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888728   Korea, Republic of;
      2021   Phase 1   NCT04888715   Korea, Republic of;
Dabigatran   
   University College, London
      2016   -   NCT02885961   -
Dasatinib + Quercetin   
   Wake Forest University Health Sciences
      2016   Phase 1   NCT02874989   United States;
Dextromethorphan   
   Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR2000037602   China;
Diet A group   
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04767815   Korea, Republic of;
Diet B group   
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04767815   Korea, Republic of;
Diet C group   
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04767815   Korea, Republic of;
Disodium Cromoglycate [cromolyn sodium]   
   Patara Pharma
      2015   -   EUCTR2014-004025-40-NL   Netherlands;United Kingdom;
      2014   Phase 2   EUCTR2014-004025-40-GB   Netherlands;United Kingdom;
Disodium cromoglycate (DSCG)   
   Patara Pharma
      2015   -   EUCTR2014-004025-40-NL   Netherlands;United Kingdom;
      2014   Phase 2   EUCTR2014-004025-40-GB   Netherlands;United Kingdom;
Durvalumab   
   Fujimoto Daichi
      2021   -   JPRN-jRCTs051200109   Japan;
ESBRIET - 267 MG - CAPSULA RIGIDA - USO ORALE - FLACONE (HDPE) 270 CAPSULE   
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
EZ-2053   
   Neovii Biotech
      2005   Phase 3   NCT00105183   Australia;Austria;Canada;United States;
Endobronchial infusion of adult mesenchymal stem cells   
   Clinica Universidad de Navarra, Universidad de Navarra
      2013   Phase 1   NCT01919827   Spain;
Epigallocatechin-3-gallate (EGCG)   
   University of California, San Francisco
      2018   Early Phase 1   NCT03928847   United States;
Erivedge   
   F. Hoffmann-La Roche Ltd.
      2014   -   EUCTR2014-000963-42-DE   Australia;Chile;France;Germany;Israel;Italy;Korea, Republic of;Mexico;New Zealand;Peru;Spain;United States;
Esbriet   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim France
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States;
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Esbriet® (Pirfenidon)   
   Justus Liebig Universität Giessen
      2015   Phase 2   EUCTR2014-000861-32-DE   Germany;
Etanercept   
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 2   NCT00063869   United States;
Etoposide   
   Fujimoto Daichi
      2021   -   JPRN-jRCTs051200109   Japan;
   IKEDA Satoshi
      2019   Phase 2   JPRN-jRCTs031190119   Japan;
FG-3019   
   FIBROGEN
      2020   Phase 3   EUCTR2020-000697-22-IT   Belgium;Brazil;Bulgaria;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom;
   FibroGen
      2011   Phase 2   NCT01262001   United States;
      1994   Phase 1   NCT00074698   United States;
   FibroGen, Inc.
      2021   Phase 3   EUCTR2020-000697-22-IE   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
      2020   Phase 3   EUCTR2020-000697-22-NL   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
      2020   Phase 3   EUCTR2020-000697-22-HU   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;India;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Peru;Poland;Serbia;Spain;Ukraine;United Kingdom;
      2020   Phase 3   EUCTR2020-000697-22-DK   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
      2020   Phase 3   EUCTR2020-000697-22-DE   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;
FG-3019 10mg/mL in 10 mL vials   
   FibroGen, Inc.
      2016   Phase 2   EUCTR2014-005658-20-BG   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
FLUORINE (18F) FLUDEOXYGLUCOSE   
   Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik
      2010   -   EUCTR2010-020223-44-AT   Austria;
Fludarabine   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
Fluimucil® 600 mg effervescent tablets   
   InterMune International AG.
      2013   Phase 2   EUCTR2012-000564-14-GB   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-SE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-IT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-DK   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-DE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-BE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-AT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
Formoterol fumarate dihydrate   
   Hull and East Yorkshire Hospitals NHS Trust
      2014   -   EUCTR2013-004404-19-GB   United Kingdom;
Fostair   
   Hull University Teaching Hospitals NHS Trust
      2014   Phase 2   NCT02048644   United Kingdom;
   Hull and East Yorkshire Hospitals NHS Trust
      2014   -   EUCTR2013-004404-19-GB   United Kingdom;
G-CSF   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
G048E03   
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
G321605   
   Galapagos NV
      2019   Phase 2   EUCTR2017-004302-18-HR   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2019   Phase 2   EUCTR2017-004302-18-FI   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-SK   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-SE   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-FR   Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-BG   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
G451990   
   GALAPAGOS NV
      2018   Phase 3   EUCTR2018-001406-29-IT   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2016   Phase 2   EUCTR2015-004157-41-IT   Italy;United Kingdom;
   Galapagos NV
      2019   Phase 3   EUCTR2018-001406-29-NL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001406-29-HU   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001406-29-FR   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001405-87-GR   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-GB   Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-DE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-CZ   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-BE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001406-29-PL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2018   Phase 3   EUCTR2018-001405-87-ES   Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001405-87-DK   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004157-41-GB   Ukraine;United Kingdom;
GB0139   
   Galecto Biotech AB
      2019   Phase 2   NCT03832946   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
GB0139 (previously known as TD139)   
   Galecto Biotech AB
      2020   Phase 2   EUCTR2018-002664-73-IE   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-PL   Australia;Belgium;Canada;France;Georgia;Germany;Ireland;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
GBT440   
   Global Blood Therapeutics
      2016   Phase 2   NCT02989168   United Kingdom;United States;
      2016   Phase 2   NCT02846324   United States;
GBT440 300 mg capsule   
   Global Blood Therapeutics Inc.
      2017   Phase 2   EUCTR2017-001276-27-GB   United Kingdom;United States;
GBT440 300 mg tablet   
   Global Blood Therapeutics Inc.
      2017   Phase 2   EUCTR2017-001276-27-GB   United Kingdom;United States;
GC1008   
   Genzyme, a Sanofi Company
      2005   Phase 1   NCT00125385   Belgium;United States;
GKT137831   
   University of Alabama at Birmingham
      2020   Phase 2   NCT03865927   United States;
GLPG1205   
   Galapagos NV
      2019   Phase 2   EUCTR2017-004302-18-HR   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2019   Phase 2   EUCTR2017-004302-18-FI   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   NCT03725852   Bulgaria;Croatia;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-SK   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-SE   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-FR   Bulgaria;Croatia;Egypt;Finland;France;Lebanon;Oman;Romania;Slovakia;Sweden;Ukraine;
      2018   Phase 2   EUCTR2017-004302-18-BG   Bulgaria;Croatia;Egypt;Finland;France;Oman;Romania;Slovakia;Sweden;Ukraine;
GLPG1690   
   GALAPAGOS NV
      2018   Phase 3   EUCTR2018-001406-29-IT   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2016   Phase 2   EUCTR2015-004157-41-IT   Italy;United Kingdom;
   Galapagos NV
      2019   Phase 3   EUCTR2018-001406-29-NL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001406-29-HU   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001406-29-FR   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001405-87-GR   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-GB   Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-DE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-CZ   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-BE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   NCT03733444   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2018   Phase 3   NCT03711162   Australia;Belgium;Brazil;Chile;Czechia;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001406-29-PL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2018   Phase 3   EUCTR2018-001405-87-ES   Australia;Belgium;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001405-87-DK   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004157-41-GB   Ukraine;United Kingdom;
GLPG1690 600 mg QD   
   Galapagos NV
      2016   Phase 2   NCT02738801   Italy;Ukraine;United Kingdom;
GS-6624   
   Gilead Sciences
      2010   Phase 1   NCT01362231   United States;
   Gilead Sciences, Inc.
      2013   Phase 2   EUCTR2012-001571-36-GB   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-001571-36-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-001571-36-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-PL   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-IT   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-ES   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-DE   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
GSK2126458   
   GlaxoSmithKline
      2013   Phase 1   NCT01725139   United Kingdom;
GSK3008348   
   GlaxoSmithKline
      2017   Phase 1   NCT03069989   United Kingdom;
GSK3008348 Nebuliser solution   
   GlaxoSmithKline
      2015   Phase 1   NCT02612051   United Kingdom;
Gallium68-Dota-Noc   
   AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
      2012   -   EUCTR2011-003687-78-IT   Italy;
      2009   -   EUCTR2008-007168-40-IT   Italy;
Gefapixant   
   Afferent Pharmaceuticals, Inc.
      2015   Phase 2   NCT02502097   United States;
      2015   Phase 2   NCT02477709   United States;
Granulocyte Colony Stimulating Factor   
   Shanghai Pulmonary Hospital
      2015   -   ChiCTR-OOC-15005862   China;
HEC 68498   
   Sunshine Lake Pharma Co., Ltd.
      2018   Phase 1   NCT03502902   United States;
HEC585   
   Sunshine Lake Pharma Co., Ltd.
      2020   Phase 1   NCT04512170   China;
      2017   Phase 1   NCT03092102   United States;
HZN-825   
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2021-001253-32-GR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-001253-32-ES   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
      2021   Phase 2   NCT05032066   United States;
High dose BIBF 1120 twice daily   
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Humanized anti-alpha v beta 6 mAb   
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2017-003158-18-IT   Argentina;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Biogen Idec Research Limited
      2019   Phase 2   EUCTR2017-003158-18-PL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003158-18-DE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-NL   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-GR   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-GB   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-ES   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-DK   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-CZ   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003158-18-BE   Argentina;Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Hydroxyurea   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
Hyperoxia   
   University of British Columbia
      2022   -   NCT03800017   -
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment   
   Duke University
      2020   Phase 2   NCT04071769   United States;
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment   
   Duke University
      2022   Phase 2   NCT05241275   -
Hyperpolarized 129-Xenon gas   
   Bastiaan Driehuys
      2015   Phase 1   NCT02478268   United States;
Hyperpolarized Xe129   
   University of Kansas Medical Center
      2022   Phase 2   NCT04677426   -
IDL-2965 Oral Capsule   
   Indalo Therapeutics, Inc.
      2019   Phase 1   NCT03949530   United Kingdom;
INO   
   Bellerophon Pulse Technologies LLC
      2014   Phase 1;Phase 2   EUCTR2014-003423-21-BE   Belgium;
INOmax 400ppm mol/mol inhalation gas   
   Bellerophon Pulse Technologies LLC
      2014   Phase 1;Phase 2   EUCTR2014-003423-21-BE   Belgium;
INS018_055   
   InSilico Medicine Hong Kong Limited
      2022   Phase 1   NCT05154240   New Zealand;
IV Deployment Of cSVF In Sterile Normal Saline IV Solution   
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States;
IW001   
   ImmuneWorks
      2010   Phase 1   NCT01199887   United States;
Ifenprodil   
   Algernon Pharmaceuticals
      2020   Phase 2   NCT04318704   Australia;New Zealand;
Iloprost Inhalation Solution (Ventavis)   
   Actelion
      2005   Phase 2   NCT00109681   United States;
Imatinib Mesylate (Gleevec)   
   Daniels, Craig E., M.D.
      2003   Phase 2/Phase 3   NCT00131274   -
Immukin   
   InterMune
      2005   Phase 3   EUCTR2004-001261-17-IE   Ireland;
      2005   Phase 3   EUCTR2004-000029-31-IE   Ireland;
Inhaled Nitric Oxide   
   Geno LLC
      2011   Phase 2   NCT01265888   United States;
Inhaled Nitric Oxide - 30 mcg/kg IBW/hr   
   Bellerophon
      2015   Phase 1   NCT02267655   Belgium;
Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr   
   Bellerophon
      2015   Phase 1   NCT02267655   Belgium;
Inhaled TD139   
   Galecto Biotech AB
      2014   Phase 1/Phase 2   NCT02257177   United Kingdom;
Inhaled Treprostinil   
   United Therapeutics
      2022   Phase 3   NCT05255991   -
      2022   Phase 3   NCT04905693   -
      2021   Phase 3   NCT04708782   United States;
Inhaled carbon monoxide   
   Brigham and Women's Hospital
      2011   Phase 2   NCT01214187   United States;
Inhaled nitric oxide 75 mcg/kg IBW/hr   
   Bellerophon
      2015   Phase 1   NCT02267655   Belgium;
Interferon alpha oral lozenge   
   Texas Tech University Health Sciences Center
      2000   Phase 2   NCT01442779   United States;
Interferon gamma-1b   
   InterMune
      2005   Phase 3   EUCTR2004-001261-17-IE   Ireland;
      2005   Phase 3   EUCTR2004-000029-31-IE   Ireland;
      2003   Phase 3   NCT00076635   United States;
Interferon gamma-1b (Actimmune)   
   InterMune
      2003   Phase 3   NCT00075998   United States;
Interferon-alpha lozenges   
   Amarillo Biosciences, Inc.
      2008   Phase 2   NCT00690885   United States;
Interferon-gamma 1b   
   InterMune
      2002   Phase 3   NCT00052039   Italy;
      2002   Phase 2   NCT00052052   United States;
      2001   Phase 2   NCT00047658   United States;
      2000   Phase 3   NCT00047645   United States;
Intermediate dose BIBF 1120 twice daily   
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets   
   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
      2020   Phase 2   NCT04312594   China;
Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets   
   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
      2020   Phase 2   NCT04312594   China;
Jin-shui Huan-xian granule   
   Henan University of Traditional Chinese Medicine
      2020   -   NCT04187690   China;
KD025   
   Kadmon Corporation, LLC
      2016   Phase 2   NCT02688647   United States;
L - Antineoplastic and immunomodulating agents   
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain;
L01 - Antineoplastic agents   
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain;
L01X - Other antineoplastic agents   
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain;
L01XE - Protein kinase inhibitors   
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain;
L01XE31 - Nintedanib   
   Boehringer Ingelheim
      2017   -   NCT03281200   Spain;
LANREOTIDE ACETATE   
   AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
      2012   -   EUCTR2011-003687-78-IT   Italy;
LPA1   
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2020   Phase 2   EUCTR2019-003992-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2020   Phase 2   EUCTR2019-003992-21-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;Taiwan;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003992-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Lansoprazole   
   Huang Jinhong
      2021   Phase 1   JPRN-jRCT2071210016   Japan;
   Norfolk and Norwich University Hospitals NHS Foundation Trust
      2021   Phase 3   NCT04965298   United Kingdom;
      2020   Phase 3   EUCTR2020-000041-14-GB   United Kingdom;
Lebrikizumab   
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 2   JPRN-JapicCTI-142708   -
   Hoffmann-La Roche
      2013   Phase 2   NCT01872689   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Letairis   
   Gilead Sciences Incorporated
      2010   -   EUCTR2008-004405-34-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-004405-34-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-011169-98-IT   Austria;Czech Republic;Germany;Italy;United Kingdom;
      2009   -   EUCTR2008-004405-34-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-004405-34-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      -   -   EUCTR2008-004405-34-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Gilead Sciences, Inc
      2009   -   EUCTR2009-011169-98-GB   Austria;Czech Republic;Germany;Italy;United Kingdom;
      2009   -   EUCTR2009-011169-98-DE   Austria;Czech Republic;Germany;Italy;United Kingdom;
      2009   -   EUCTR2009-011169-98-AT   Austria;Czech Republic;Germany;Italy;United Kingdom;
   Gilead Sciences, Inc.
      2011   -   EUCTR2009-011169-98-CZ   Austria;Czech Republic;Germany;Italy;United Kingdom;
Letermovir   
   Fernanda P Silveira, MD, MS
      2021   Phase 2   NCT05041426   United States;
Liberase Enzyme (Roche)   
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States;
Losartan   
   University of South Florida
      2009   -   NCT00879879   United States;
Low dose BIBF 1120 twice daily   
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Low dose BIBF1120 once daily   
   Boehringer Ingelheim
      2007   Phase 2   NCT00514683   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;El Salvador;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;South Africa;Spain;Taiwan;Turkey;United Kingdom;
Lung Spheroid Stem Cells 100 million   
   University of North Carolina, Chapel Hill
      2020   Phase 1   NCT04262167   United States;
Lung Spheroid Stem Cells 200 million   
   University of North Carolina, Chapel Hill
      2020   Phase 1   NCT04262167   United States;
Lung stem cells   
   Shanghai East Hospital
      2016   Phase 1/Phase 2   NCT02745184   China;
MG-S-2525   
   Metagone Biotech Inc.
      2019   Phase 1   NCT03650075   Taiwan;
MRI   
   Bastiaan Driehuys
      2015   Phase 1   NCT02478268   United States;
Macitentan   
   ACTELION Pharmaceuticals Ltd.
      2011   -   EUCTR2010-024211-13-SI   Australia;Canada;Germany;Israel;Slovenia;South Africa;Spain;Sweden;Turkey;United States;
      2011   -   EUCTR2010-024211-13-SE   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
      2011   -   EUCTR2010-024211-13-ES   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
      2011   -   EUCTR2010-024211-13-DE   Australia;Canada;Germany;Israel;South Africa;Spain;Sweden;Turkey;United States;
   Actelion
      2011   Phase 2   NCT01346930   -
   Actelion Pharamceuticals Ltd
      2010   -   EUCTR2008-006054-17-IT   France;Germany;Italy;Slovenia;Spain;Sweden;
   Actelion Pharmaceuticals Ltd.
      2009   Phase 2   EUCTR2008-006054-17-ES   France;Germany;Italy;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-006054-17-SI   France;Germany;Italy;Slovenia;Spain;Sweden;
      2009   -   EUCTR2008-006054-17-SE   France;Germany;Italy;Slovenia;Spain;Sweden;
      -   -   EUCTR2008-006054-17-DE   France;Germany;Italy;Slovenia;Spain;Sweden;
Medical air   
   Queen's University
      2021   Early Phase 1   NCT05052229   Canada;
   Schön Klinik Berchtesgadener Land
      2016   -   NCT03050255   Germany;
Medical air (sham O2)   
   George Papanicolaou Hospital
      2018   -   NCT03688334   Greece;
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)   
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States;
Minocycline   
   University of California, Los Angeles
      2006   Phase 3   NCT00203697   United States;
Montelukast   
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
   Shanghai Pulmonary Hospital
      2015   -   ChiCTR-OOC-15005841   -
Morphine Sulfate   
   Royal Brompton & Harefield NHS Foundation Trust
      2020   Phase 3   NCT04429516   United Kingdom;
Morphine hydrochloride   
   Medical University of Gdansk
      2020   Phase 3   NCT04497831   -
Moxifloxacin   
   Respiratory Department, Peking Union Medical College Hospital
      2011   -   ChiCTR-TRC-12002372   China;
Mycophenolate mofetil   
   Peking Union Medical College Hospital
      2019   Phase 4   ChiCTR1900027121   China;
N-Acetylcysteine, (NAC)   
   InterMune International AG.
      2013   Phase 2   EUCTR2012-000564-14-GB   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-SE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-IT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-DK   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-DE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-BE   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
      2013   -   EUCTR2012-000564-14-AT   Austria;Belgium;Denmark;Germany;Italy;Sweden;United Kingdom;
N-acetyl cysteine   
   University of Colorado, Denver
      2022   Phase 1/Phase 2   NCT03720483   United States;
   Weill Medical College of Cornell University
      2020   Phase 3   NCT04300920   United States;
N-acetylcysteine   
   Hoffmann-La Roche
      2013   Phase 2   NCT02707640   Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom;
   Zambon SpA
      2000   Phase 3   NCT00639496   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
NAC   
   Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
      2009   -   JPRN-UMIN000016045   Japan;
   Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
      2015   -   JPRN-UMIN000015508   Japan;
   Shanghai Pulmonary Hospital, Tongji University School of Medicine
      2020   -   ChiCTR2000031386   China;
   Toho University Omori Medical CenterDepartment of Respiratory Medicine
      2009   -   JPRN-UMIN000007663   Japan;
NALBUPHINE HYDROCHLORIDE   
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom;
ND-L02-s0201   
   Nitto Denko Corporation
      2018   Phase 2   NCT03538301   Germany;Japan;United Kingdom;United States;
ND-L02-s0201 for injection   
   Nitto Denko Corporation
      2018   Phase 2   EUCTR2017-004919-39-DE   Germany;Japan;United Kingdom;United States;
NIP292 tablet   
   The National Institutes of Pharmaceutical R&D Co. Ltd, China
      2019   Phase 1   NCT04720443   United States;
NIP292 tablets   
   The National Institutes of Pharmaceutical R&D Co. Ltd, China
      2019   Phase 1   NCT04720443   United States;
Nalbuphine ER   
   Trevi Therapeutics
      2019   Phase 2   NCT04030026   United Kingdom;
Nalbuphine Extended-Realease (ER) Tablets   
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom;
Nalbuphine Extended-Release (ER) Tablets   
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom;
Nebivolol   
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888728   Korea, Republic of;
Nintedanib   
   BOEHRINGER ING.
      2012   Phase 3   EUCTR2011-002766-21-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim
      2021   -   NCT05022784   United States;
      2021   -   NCT04739150   Belgium;
      2021   -   NCT04525547   Korea, Republic of;
      2019   -   NCT03958071   United States;
      2019   -   NCT03710824   Greece;
      2018   Phase 4   NCT03717012   United States;
      2016   Phase 4   NCT02788474   Australia;Belgium;Czech Republic;Czechia;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 4   NCT02606877   United Kingdom;
      2016   Phase 3   NCT02802345   Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
      2015   Phase 4   NCT02579603   Canada;France;Germany;Italy;Netherlands;United States;
      2015   -   NCT02607722   Japan;
      2014   -   NCT02230982   Brazil;
      2014   -   NCT02171156   United States;
      2013   Phase 3   NCT01979952   Canada;Turkey;United States;
      2012   Phase 3   EUCTR2011-002766-21-FI   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2011   Phase 2   NCT01417156   Japan;
   Boehringer Ingelheim Hellas
      2012   Phase 3   EUCTR2011-002766-21-GR   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Boehringer Ingelheim España S.A
      2012   Phase 3   EUCTR2011-002766-21-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2013   Phase 3   EUCTR2011-002766-21-IE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-002766-21-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2012   Phase 3   EUCTR2011-002766-21-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Boehringer Ingelheim RCV GmBH & Co KG
      2010   Phase 2   EUCTR2009-013788-21-HU   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmbH & Co KG
      2012   Phase 3   EUCTR2011-002766-21-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-013788-21-CZ   Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Portugal;Russian Federation;Spain;United Kingdom;
   Central Japan Lung Study Grou
      2017   Phase 4   JPRN-UMIN000026376   Japan;
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888715   Korea, Republic of;
   Hirosaki University Graduate School of Medicine
      2016   -   JPRN-UMIN000021591   Japan;
   Hoffmann-La Roche
      2016   Phase 4   NCT02598193   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
   IKEDA Satoshi
      2019   Phase 2   JPRN-jRCTs031190119   Japan;
   Intellectual Disabilities
   Kanagawa Cardiovascular and Respiratory Center
      2016   -   JPRN-UMIN000020722   Japan;
      2015   Phase 2   JPRN-UMIN000019436   Japan;
   Kayamori Takefumi
      2021   Phase 3   JPRN-jRCT2031210008   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom;
   National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&
   Okamoto Isamu
      2017   Phase 3   JPRN-jRCTs071180049   Japan;
   Research Institute for Diseases of the Chest, Kyushu University
      2017   Phase 3   JPRN-UMIN000026799   Japan;
   SCS Boehringer Ingelheim Ingelheim Comm.V
      2012   Phase 3   EUCTR2011-002766-21-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Temple University
      2019   Phase 2   NCT03562416   United States;
   Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
      2012   Phase 3   EUCTR2011-002766-21-PT   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Czech Republic;Finland;France;Germany;Greece;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Nitric Oxide   
   Queen's University
      2021   Early Phase 1   NCT05052229   Canada;
Nivolumab   
   Kobe city medical center general hospital
      2016   -   JPRN-UMIN000022037   Japan;
None   
   Blade Therapeutics, Inc.
      2020   Phase 2   EUCTR2019-004998-34-GB   United Kingdom;
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom;
OFEV®   
   Boehringer Ingelheim
      2020   -   NCT04614441   Taiwan;
ORIN1001   
   Orinove, Inc.
      2021   Phase 1   NCT04643769   United States;
Octreotide   
   Institut National de la Santé Et de la Recherche Médicale, France
      2006   Phase 1/Phase 2   NCT00463983   France;
Ofev   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2015   Phase 4   EUCTR2015-000640-42-IT   Canada;France;Germany;Italy;Netherlands;United States;
   F. HOFFMANN - LA ROCHE LTD.
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
   F. Hoffmann-La Roche Ltd
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
Ofev 100 mg capsule   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2016   Phase 4   EUCTR2015-003148-38-ES   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2016   Phase 4   EUCTR2015-003148-38-FI   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-003148-38-FR   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim Limited
      2016   Phase 4   EUCTR2015-003148-38-GB   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 4   EUCTR2015-003148-38-DE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2016   Phase 4   EUCTR2015-003148-38-PL   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-003148-38-HU   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-003148-38-CZ   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States;
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 4   EUCTR2015-003148-38-BE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Ofev 150 mg capsule   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2016   Phase 4   EUCTR2015-003148-38-ES   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Finland Ky
      2016   Phase 4   EUCTR2015-003148-38-FI   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-003148-38-FR   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2015   Phase 4   EUCTR2015-000640-42-FR   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim Limited
      2016   Phase 4   EUCTR2015-003148-38-GB   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 4   EUCTR2015-003148-38-DE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2015   Phase 4   EUCTR2015-000640-42-DE   Canada;France;Germany;Italy;Netherlands;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2016   Phase 4   EUCTR2015-003148-38-PL   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-003148-38-HU   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 4   EUCTR2015-003148-38-CZ   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
   Boehringer Ingelheim bv
      2015   Phase 4   EUCTR2015-000640-42-NL   Canada;France;Germany;Italy;Netherlands;United States;
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 4   EUCTR2015-003148-38-BE   Australia;Belgium;Czech Republic;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Omeprazole   
   Newcastle-upon-Tyne Hospitals NHS Trust
      2014   Phase 2   NCT02085018   United Kingdom;
Omeprazole (UK licensed generic product)   
   Newcastle Upon Tyne Hospitals NHS Foundation Trust
      2013   Phase 2   EUCTR2013-003301-26-GB   United Kingdom;
Oxygen   
   Brigham and Women's Hospital
      2011   Phase 2   NCT01214187   United States;
   Department of Respiratory Medicine and Allergology, Kinki University School of Medicine
      2011   -   JPRN-UMIN000005098   Japan;
   George Papanicolaou Hospital
      2018   -   NCT03688334   Greece;
   Parc de Salut Mar
      2019   -   NCT04564664   Spain;
   Schön Klinik Berchtesgadener Land
      2016   -   NCT03050255   Germany;
   Tosei General Hospital
      2009   -   JPRN-UMIN000025256   Japan;
   University of British Columbia
      2015   -   NCT02551068   Canada;
Oxymizer® compared to CNC   
   Klinikum Berchtesgadener Land der Schön-Kliniken
      2014   -   NCT02268981   Germany;
PA101   
   Patara Pharma
      2015   Phase 2   NCT02412020   Netherlands;United Kingdom;
      2015   -   EUCTR2014-004025-40-NL   Netherlands;United Kingdom;
      2014   Phase 2   EUCTR2014-004025-40-GB   Netherlands;United Kingdom;
PBI4050   
   Liminal BioSciences Ltd.
      2015   Phase 2   NCT02538536   Canada;
PD00377 Na-salt   
   Vicore Pharma AB
      2018   Phase 2   EUCTR2017-004923-63-GB   Bulgaria;Poland;Serbia;United Kingdom;
PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714   
   University of Alabama at Birmingham
      2020   Phase 1   NCT04362644   United States;
PIR, S-7701   
   INTERMUNE
      2006   -   EUCTR2006-000252-41-IT   Italy;United Kingdom;
   InterMune, Inc.
      2008   Phase 3   EUCTR2007-007800-13-IE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-007800-13-GB   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-007800-13-ES   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-007800-13-DE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-007800-13-BE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
PLN-74809   
   Pliant Therapeutics, Inc.
      2020   Phase 2   NCT04396756   Australia;Belgium;Canada;Italy;Netherlands;New Zealand;United States;
      2019   Phase 2   NCT04072315   United States;
PLN-74809-000   
   Pliant Therapeutics Inc.
      2020   Phase 2   EUCTR2019-002709-23-IT   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002709-23-GB   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;New Zealand;United Kingdom;United States;
PLN-74809-020   
   Pliant Therapeutics Inc.
      2021   Phase 2   EUCTR2019-002709-23-NL   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002709-23-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;United Kingdom;United States;
PMG1015 Dose 1   
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia;
PMG1015 Dose 2   
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia;
PMG1015 Dose 3   
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia;
PMG1015 Dose 4   
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia;
PMG1015 Dose 5   
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia;
PMG1015 Dose 6   
   Pulmongene Ltd.
      2021   Phase 1   NCT05022771   Australia;
PRIVIGEN 100mg/ml   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2018-002632-24-FR   France;
PRM-151   
   Hoffmann-La Roche
      2021   Phase 3   NCT04594707   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;South Africa;Spain;Sweden;Switzerland;Ukraine;United States;
      2021   Phase 3   NCT04552899   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 2   NCT02550873   Belgium;Czech Republic;Czechia;Germany;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2011   Phase 1   NCT01254409   Netherlands;United States;
   Makino Ryoko
      2021   Phase 3   JPRN-jRCT2051210129   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
   PROMEDIOR, INC.
      2015   Phase 2   EUCTR2014-004782-24-IT   Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Spain;United Kingdom;United States;
   Promedior inc
      2015   -   EUCTR2014-004782-24-NL   Netherlands;
   Promedior, Inc.
      2016   Phase 2   EUCTR2014-004782-24-HU   Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 2   EUCTR2014-004782-24-ES   Belgium;Czech Republic;Germany;Hungary;Netherlands;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2014-004782-24-DE   Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 2   EUCTR2014-004782-24-CZ   Belgium;Czech Republic;France;Germany;Hungary;Netherlands;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-004782-24-BE   Belgium;Czech Republic;Germany;Hungary;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
   Shimoda Yukiko
      2022   Phase 3   JPRN-jRCT2001210001   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;South Korea;Spain;Sweden;
PZN 8881655(RochePharma AG)   
   Justus Liebig Universität Giessen
      2015   Phase 2   EUCTR2014-000861-32-DE   Germany;
Paclitaxel   
   Hirosaki University Graduate School of Medicine
      2016   -   JPRN-UMIN000021591   Japan;
   IP lung cancer study group
      2012   -   JPRN-UMIN000018322   Japan;
      2012   -   JPRN-UMIN000018248   Japan;
   Katakami Nobuyuki
      2013   Phase 2   JPRN-jRCTs061180046   Japan;
      2013   Phase 2   JPRN-jRCTs051180149   Japan;
   Lung Oncology Group in Kyushu, Japan (LOGIK)
      2007   -   JPRN-UMIN000015929   Japan;
   Okamoto Isamu
      2017   Phase 3   JPRN-jRCTs071180049   Japan;
   Research Institute for Diseases of the Chest, Kyushu University
      2017   Phase 3   JPRN-UMIN000026799   Japan;
Pamrevlumab   
   FibroGen
      2020   Phase 3   NCT04419558   Brazil;Colombia;Czechia;Denmark;Dominican Republic;France;Georgia;Germany;Hungary;Ireland;Italy;Korea, Republic of;Lebanon;Mexico;Netherlands;Peru;Poland;Serbia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03955146   Argentina;Australia;Chile;China;Czechia;France;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lebanon;Netherlands;Peru;Russian Federation;Spain;Taiwan;United States;
      2013   Phase 2   NCT01890265   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
   FibroGen, Inc.
      2016   Phase 2   EUCTR2014-005658-20-BG   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
   Tracy Ganske
      2022   Phase 3   JPRN-jRCT2051210169   Argentina;Australia;Chile;Hong Kong;Japan;Russia;South Korea;Taiwan;United States;the People's Republic of China;
Paroxetine   
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888728   Korea, Republic of;
Pirfenidone   
   Beijing Kawin Technology Share-Holding Co., Ltd.
      2012   Phase 2   NCT01504334   China;
   Boehringer Ingelheim
      2019   -   NCT03958071   United States;
      2016   Phase 4   NCT02606877   United Kingdom;
      2015   Phase 4   NCT02579603   Canada;France;Germany;Italy;Netherlands;United States;
   Bristol-Myers Squibb
      2019   Phase 1   NCT03981094   United States;
   Daewoong Pharmaceutical Co. LTD.
      2021   Phase 1   NCT04888715   Korea, Republic of;
   Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine
      2012   -   JPRN-UMIN000008541   Japan;
   Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo
      2009   -   JPRN-UMIN000016045   Japan;
   Genentech, Inc.
      2014   -   NCT02141087   -
      2011   Phase 3   NCT01366209   United States;
      2008   Phase 3   NCT00662038   United States;
      2006   Phase 3   NCT00287729   United States;
      2006   Phase 3   NCT00287716   United States;
      2003   Phase 2   NCT00080223   United States;
   Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan.
      2015   -   JPRN-UMIN000015508   Japan;
   Hoffmann-La Roche
      2017   Phase 3   NCT03208933   Russian Federation;
      2017   -   NCT03115619   Greece;
      2016   Phase 4   NCT02598193   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 2   NCT02951429   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 1   NCT02648048   Germany;United States;
      2014   -   NCT02622477   Germany;
      2013   Phase 2   NCT02707640   Austria;Belgium;Denmark;France;Germany;Italy;Sweden;United Kingdom;
      2013   Phase 2   NCT01872689   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2012   -   NCT02699879   Austria;Denmark;Finland;France;Germany;Ireland;Italy;Norway;Sweden;United Kingdom;
   INTERMUNE
      2008   -   EUCTR2007-007800-13-IT   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
   Intellectual Disabilities
   InterMune, Inc.
      2008   Phase 3   EUCTR2007-007800-13-IE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-007800-13-GB   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-007800-13-ES   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-007800-13-DE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-007800-13-FR   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2008   -   EUCTR2007-007800-13-BE   Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000252-41-GB   Italy;United Kingdom;
      2006   Phase 3   EUCTR2006-000138-11-ES   Belgium;Czech Republic;Germany;Ireland;Spain;
      2006   -   EUCTR2006-000138-11-DE   Belgium;Czech Republic;Germany;Ireland;Spain;
      2006   -   EUCTR2006-000138-11-CZ   Belgium;Czech Republic;Germany;Ireland;Spain;
      2006   -   EUCTR2006-000138-11-BE   Belgium;Czech Republic;Germany;Ireland;Spain;
   Kanagawa Cardiovascular and Respiratory Center
      2015   Phase 2   JPRN-UMIN000019436   Japan;
   Kayamori Takefumi
      2021   Phase 3   JPRN-jRCT2031210008   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Germany;Greece;Japan;Peru;Spain;Taiwan;Turkey;USA;United Kingdom;
   National Hospital Organization Ibarakihigashi National Hospital
      2015   -   JPRN-UMIN000016826   Japan;
   National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&
   North East Japan Study Group
      2017   Phase 3   JPRN-UMIN000029411   Japan;
   Saitama Medical University
      2009   -   JPRN-UMIN000005793   Japan;
   Shanghai Pulmonary Hospital, Shanghai, China
      2011   Phase 2   NCT02136992   -
   Tianjin Medical University General Hospital
      2020   Phase 4   ChiCTR2000037602   China;
   West Japan Oncology Group
      2012   Phase 2   JPRN-UMIN000007774   Japan;
Pirfenidone Solution for Inhalation   
   Avalyn Pharma, Inc.
      2021   Phase 2   EUCTR2020-005103-39-PL   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
      2021   Phase 2   EUCTR2020-005103-39-CZ   Australia;Czech Republic;Czechia;Netherlands;New Zealand;Poland;United Kingdom;
Pirfenidone and nintedanib   
   Hospices Civils de Lyon
      2020   Phase 4   NCT03939520   France;
Pirfenidone or nintedanib   
   Hospices Civils de Lyon
      2020   Phase 4   NCT03939520   France;
Pirfenidoneone   
   Boehringer Ingelheim
      2011   Phase 2   NCT01417156   Japan;
Placebo   
   ASAHI KASEI PHARMA CORPORATION
      2016   Phase 3   JPRN-JapicCTI-163326   -
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 2   JPRN-JapicCTI-142708   -
Pomalidomide (CC-4047   
   Stanford University
      2010   Phase 2   NCT01135199   United States;
Prednisone   
   Hospital Universitari Vall d'Hebron Research Institute
      2020   Phase 4   NCT04534478   -
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
QAX576   
   Novartis Pharma Services AG
      2011   -   EUCTR2010-020688-18-GB   United Kingdom;
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01266135   United Kingdom;United States;
      2007   Phase 2   NCT00532233   United States;
RO0220912   
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2015   Phase 4   EUCTR2015-003280-11-IT   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 4   EUCTR2015-003280-11-NL   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DK   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 4   EUCTR2015-003280-11-DE   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
   Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd
      2015   Phase 4   EUCTR2015-003280-11-ES   Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United States;
RO0280296   
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2015-005131-40-HU   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2017   Phase 2   EUCTR2015-005131-40-CZ   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-NL   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-GR   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-ES   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-DE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
      2016   Phase 2   EUCTR2015-005131-40-BE   Belgium;Canada;Czech Republic;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
RO5490255   
   Chugai Pharmaceutical Co., Ltd.
      2014   Phase 2   JPRN-JapicCTI-142708   -
RO5490255/F01-02   
   F. Hoffmann-La Roche Ltd
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
RO7490677   
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-001429-30-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000791-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/ F01-02   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-01   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-02   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7490677/F01-03   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RVT-1601   
   Respivant Sciences GmbH
      2019   Phase 2   NCT03864328   Australia;Belgium;Canada;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RVT-1601 (formerly, PA101B)   
   Respivant Sciences GmbH
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RVT-1601 (in precedenza PA101B)   
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
RXC007   
   Redx Pharma Plc
      2021   Phase 1   NCT04931147   United Kingdom;
Recombinant human Pentraxin-2 (PRM-151)   
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-001429-30-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000791-38-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001429-30-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001429-30-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-GR   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000791-38-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Remicade   
   Academic Medical Centre
      2007   -   EUCTR2004-001876-37-DE   Germany;
Revatio   
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2016   Phase 3   EUCTR2015-002619-14-IT   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim España, S.A.
      2016   Phase 3   EUCTR2015-002619-14-ES   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim France
      2017   Phase 3   EUCTR2015-002619-14-FR   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2016   Phase 3   EUCTR2015-002619-14-GB   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2016   Phase 3   EUCTR2015-002619-14-DE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm. V
      2016   Phase 3   EUCTR2015-002619-14-BE   Australia;Belgium;Canada;China;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
Rituximab   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
   University of Alabama at Birmingham
      2014   Phase 2   NCT01969409   United States;
Ro 47-0203   
   ACTELION PHARMACEUTICALS LTD
      2007   Phase 3   EUCTR2006-001183-24-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-001183-24-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-001183-24-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-001183-24-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Actelion Pharmaceuticals Ltd
      2009   -   EUCTR2007-001741-18-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-001741-18-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-001741-18-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
Routine steroid administration group   
   Yonsei University
      2021   -   NCT04996303   Korea, Republic of;
SAR100842   
   Horizon Therapeutics Ireland DAC
      2022   Phase 2   EUCTR2021-001253-32-GR   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-001253-32-ES   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Italy;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
SAR156597   
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2015   Phase 2   EUCTR2014-003933-24-IT   Czech Republic;Denmark;France;Germany;Greece;Italy;Portugal;Spain;United Kingdom;
   Sanofi
      2015   Phase 2   NCT02345070   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2012   Phase 1/Phase 2   NCT01529853   Belgium;Canada;Chile;Mexico;Spain;United States;
   sanofi-aventis recherche & développement
      2016   Phase 2   EUCTR2014-003933-24-PT   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-GR   Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-GB   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-FR   Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-ES   Argentina;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-DK   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-DE   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-003933-24-CZ   Argentina;Australia;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Korea, Republic of;Mexico;Portugal;Spain;Turkey;United Kingdom;United States;
SEPTRIN   
   Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
      2013   Phase 3   EUCTR2012-005409-38-ES   Spain;
SHR-1906   
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2021   Phase 1   NCT04986540   -
SM04646   
   Samumed LLC
      1900   Phase 2   NCT03591926   Australia;New Zealand;
SODIUM CROMOGLICATE   
   Respivant Sciences GmbH
      2019   Phase 2   EUCTR2018-004447-23-NL   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-GB   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-DE   Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004447-23-BE   Australia;Belgium;Canada;Czech Republic;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
   Respivant Sciences, GmbH
      2019   Phase 2   EUCTR2018-004447-23-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Italy;Netherlands;New Zealand;Turkey;United Kingdom;United States;
Salbutamol   
   Royal Brompton & Harefield NHS Foundation Trust
      2012   Phase 1   NCT01457261   United Kingdom;
Saracatinab   
   National Jewish Health
      2020   Phase 1/Phase 2   NCT04598919   United States;
Septrin   
   University of East Anglia
      2007   -   EUCTR2007-002324-15-GB   United Kingdom;
Sildenafil   
   Boehringer Ingelheim
      2016   Phase 3   NCT02802345   Australia;Belgium;Canada;France;Germany;India;Italy;Japan;Korea, Republic of;Mexico;Spain;United Kingdom;United States;
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 2   EUCTR2015-005131-40-IT   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
   Hoffmann-La Roche
      2016   Phase 2   NCT02951429   Belgium;Canada;Czech Republic;Czechia;Egypt;Germany;Greece;Hungary;Israel;Italy;Netherlands;South Africa;Spain;Turkey;United Arab Emirates;
   Rabin Medical Center
      2011   Phase 4   NCT01382368   Israel;
   University of California, Los Angeles
      2007   Phase 4   NCT00625079   United States;
   VA Office of Research and Development
      2006   Phase 2   NCT00359736   United States;
Sildenafil (50 mg)   
   National Heart, Lung, and Blood Institute (NHLBI)
      2004   Phase 2   NCT00352482   United States;
Sildenafil Citrate   
   Duke University
      2007   Phase 3   NCT00517933   United States;
Sildenafil and Losartan   
   Alicia Gerke
      2009   Phase 2/Phase 3   NCT00981747   United States;
Simtuzumab   
   Gilead Sciences
      2013   Phase 2   NCT01769196   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
      2012   Phase 2   NCT01759511   United States;
   Gilead Sciences, Inc.
      2013   Phase 2   EUCTR2012-001571-36-GB   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-001571-36-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-001571-36-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Spain;Switzerland;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-PL   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-IT   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-ES   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-001571-36-DE   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Sirolimus   
   University of Virginia
      2011   -   NCT01462006   United States;
Sivelestat   
   Japanese Northern East Area Thoracic Surgery Study Group (JNETS)
      2013   Phase 3   JPRN-UMIN000021109   Japan;
Sterile Normal Saline for Intravenous Use   
   Black Tie Medical, Inc.
      2020   Early Phase 1   NCT04326036   United States;
Steroid pulse therapy group   
   Yonsei University
      2021   -   NCT04996303   Korea, Republic of;
Sub-Study: Nintedanib   
   FibroGen
      2013   Phase 2   NCT01890265   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Sub-Study: Pirfenidone   
   FibroGen
      2013   Phase 2   NCT01890265   Australia;Bulgaria;Canada;India;New Zealand;South Africa;United States;
Sulphamethoxazole   
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom;
Symbicort   
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
TBC   
   Nitto Denko Corporation
      2018   Phase 2   EUCTR2017-004919-39-DE   Germany;Japan;United Kingdom;United States;
TD-1058   
   Theravance Biopharma
      2020   Phase 1   NCT04589260   United Kingdom;
TD139   
   Galecto Biotech AB
      2019   Phase 2   EUCTR2018-002664-73-IT   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-GB   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-FR   Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002664-73-ES   Belgium;Canada;France;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States;
TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A   
   F. Hoffmann-La Roche Ltd
      2014   Phase 2   EUCTR2013-001163-24-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-PL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-ES   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2013-001163-24-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Mexico;Peru;Poland;Spain;United Kingdom;United States;
TR0311   
   Trevi Therapeutics, Inc.
      2019   Phase 2   EUCTR2018-004744-31-GB   United Kingdom;
TRACLEER   
   Actelion Pharmaceuticals LTD
      2006   -   EUCTR2006-001183-24-IT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Actelion Registration Ltd
      2008   -   EUCTR2007-001741-18-IT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
TRK-250   
   Toray Industries, Inc
      2018   Phase 1   NCT03727802   United States;
Tacrolimus   
   Peking Union Medical College Hospital
      2019   Phase 4   ChiCTR1900027121   China;
Taladegib   
   Endeavor Biomedicines, Inc.
      2021   Phase 2   NCT04968574   Australia;Malaysia;
Tetrandrine   
   The First People's Hospital of Yancheng
      2020   Phase 0   ChiCTR2000030400   China;
Tetrathiomolybdate   
   University of Michigan
      2003   Phase 1/Phase 2   NCT00189176   United States;
Thalidomide   
   Johns Hopkins University
      2007   Phase 3   NCT00600028   United States;
      2003   Phase 2   NCT00162760   United States;
Thalidomide Pharmion   
   University of Nottingham
      2011   -   EUCTR2010-023828-24-GB   United Kingdom;
The Standard Steroid Treatment, Plasma Exchange and rituximab   
   University of Pittsburgh
      2012   Phase 2   NCT01524068   United States;
Thiotepa   
   Paul Szabolcs
      2018   Phase 1/Phase 2   NCT03500731   United States;
Tiotropium   
   Saitama Medical University
      2009   -   JPRN-UMIN000005793   Japan;
Tipelukast   
   MediciNova
      2016   Phase 2   NCT02503657   United States;
Tracleer   
   ACTELION PHARMACEUTICALS LTD
      2007   Phase 3   EUCTR2006-001183-24-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-001183-24-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-001183-24-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-001183-24-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-001183-24-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      -   Phase 3   EUCTR2006-001183-24-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom;
   Actelion Pharmaceuticals Ltd
      2009   -   EUCTR2007-001741-18-AT   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-001741-18-GB   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-001741-18-FR   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-NL   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-ES   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-DE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-CZ   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-001741-18-BE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Royal Brompton and Harefield NHS Trust
      2007   -   EUCTR2007-001645-17-GB   United Kingdom;
Traditional Chinese Medicine Formulation   
   Xuzhou Traditional Chinese Medicine Hospital
      2018   -   NCT03711435   China;
Tralokinumab   
   MedImmune LLC
      2012   Phase 2   NCT01629667   Australia;Canada;Israel;Korea, Republic of;Peru;United States;
Tralokinumab cohort 1   
   AstraZeneca
      2014   Phase 2   NCT02036580   Japan;
Tralokinumab cohort 2   
   AstraZeneca
      2014   Phase 2   NCT02036580   Japan;
Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor   
   AstraZeneca
      -   Phase 2   JPRN-JapicCTI-142452   -
Treatment as Usual (TAU)   
   University of Alabama at Birmingham
      2018   Phase 2   NCT03286556   United States;
Treprostinil   
   Rajan Saggar
      2008   Phase 2   NCT00705133   United States;
Treprostinil Ultrasonic Nebulizer   
   United Therapeutics
      2022   Phase 3   NCT05255991   -
      2022   Phase 3   NCT04905693   -
      2021   Phase 3   NCT04708782   United States;
Treprostinil sodium for inhalation   
   Lung Biotechnology PBC
      2008   Phase 2   NCT00703339   United States;
Trimethoprim   
   Norfolk and Norwich University Hospital NHS Foundation Trust
      2014   Phase 3   EUCTR2014-004058-32-GB   United Kingdom;
VAY736   
   Novartis Pharma AG
      2018   Phase 2   EUCTR2017-002667-17-IT   Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002667-17-IE   Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002667-17-GB   Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002667-17-FR   Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002667-17-DE   Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
   Novartis Pharmaceuticals
      2017   Phase 2   NCT03287414   Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
VRP700   
   Verona Pharma plc
      2013   -   EUCTR2012-005794-31-GB   United Kingdom;
Valganciclovir   
   Fernanda P Silveira, MD, MS
      2021   Phase 2   NCT05041426   United States;
   Vanderbilt University Medical Center
      2018   Phase 1   NCT02871401   United States;
Vasoactive intestinal peptide   
   Mondobiotech Laboratories Anstalt
      2006   -   EUCTR2006-002174-22-DE   Germany;
Vismodegib   
   Hoffmann-La Roche
      2016   Phase 1   NCT02648048   Germany;United States;
      2014   Phase 2   NCT02168530   Australia;France;Germany;Israel;Korea, Republic of;Mexico;Peru;United States;
Warfarin   
   Duke University
      2009   Phase 3   NCT00957242   United States;
ZL-2102   
   Zai Lab Pty. Ltd.
      2015   Phase 1   NCT02397005   Australia;
ZSP1603   
   Guangdong Raynovent Biotech Co., Ltd
      2021   Phase 1/Phase 2   NCT05119972   China;
   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
      2018   Phase 1   NCT03619616   China;
Zileuton   
   University of Michigan
      2001   Phase 2   NCT00262405   United States;
Ziritaxestat   
   Galapagos NV
      2019   Phase 3   EUCTR2018-001406-29-HU   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2019   Phase 3   EUCTR2018-001405-87-GR   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-GB   Australia;Belgium;Brazil;Chile;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-DE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-CZ   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001405-87-BE   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-001406-29-PL   Argentina;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;South Africa;United States;
      2018   Phase 3   EUCTR2018-001405-87-DK   Australia;Belgium;Brazil;Chile;Czech Republic;Denmark;Finland;Germany;Greece;Peru;Spain;Taiwan;Turkey;United Kingdom;United States;
[18F]-FBA-A20FMDV2   
   GlaxoSmithKline
      2017   Phase 1   NCT03069989   United Kingdom;
[18F]FP-R01-MG-F2   
   Stanford University
      2017   Early Phase 1   NCT03183570   United States;
[68Ga]CBP8   
   Massachusetts General Hospital
      2018   Phase 1   NCT03535545   United States;